AlphaQuest LLC Makes New $44,000 Investment in Monopar Therapeutics Inc. $MNPR

AlphaQuest LLC purchased a new position in shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 1,215 shares of the company’s stock, valued at approximately $44,000.

Other large investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. acquired a new position in Monopar Therapeutics during the 4th quarter worth approximately $45,000. Gerber LLC acquired a new position in Monopar Therapeutics during the 1st quarter worth approximately $204,000. Point72 Asset Management L.P. acquired a new position in Monopar Therapeutics during the 4th quarter worth approximately $3,694,000. Finally, Janus Henderson Group PLC acquired a new position in Monopar Therapeutics during the 4th quarter worth approximately $23,435,000. Institutional investors and hedge funds own 1.83% of the company’s stock.

Insider Buying and Selling at Monopar Therapeutics

In other Monopar Therapeutics news, Director Kim R. Tsuchimoto sold 8,904 shares of the firm’s stock in a transaction on Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $356,160.00. Following the completion of the sale, the director owned 11,486 shares of the company’s stock, valued at $459,440. This trade represents a 43.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Chandler Robinson sold 16,800 shares of the firm’s stock in a transaction on Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $672,000.00. Following the sale, the chief executive officer directly owned 73,472 shares of the company’s stock, valued at $2,938,880. This represents a 18.61% decrease in their position. The disclosure for this sale can be found here. Insiders sold 42,504 shares of company stock valued at $1,700,160 in the last quarter. 20.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on MNPR shares. Oppenheimer started coverage on Monopar Therapeutics in a research report on Wednesday. They set an “outperform” rating and a $77.00 price target for the company. HC Wainwright began coverage on Monopar Therapeutics in a report on Tuesday, August 26th. They issued a “buy” rating and a $70.00 price objective for the company. Raymond James Financial began coverage on Monopar Therapeutics in a report on Tuesday. They issued a “strong-buy” rating and a $80.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $74.00 price objective on shares of Monopar Therapeutics in a report on Wednesday, August 27th. Finally, Chardan Capital reissued a “buy” rating and issued a $60.00 price objective on shares of Monopar Therapeutics in a report on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $69.57.

Monopar Therapeutics Trading Up 7.3%

NASDAQ MNPR opened at $38.84 on Friday. The stock has a 50 day moving average of $38.11 and a 200-day moving average of $36.65. Monopar Therapeutics Inc. has a 12 month low of $2.29 and a 12 month high of $54.30. The company has a market cap of $239.64 million, a PE ratio of -11.66 and a beta of 1.20.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.12. As a group, sell-side analysts predict that Monopar Therapeutics Inc. will post -1.65 EPS for the current fiscal year.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.